BGI News More Academic and Education More Research Collaboration More BGI in the news More
Contact Us

Media Contact

Tel: +86-755-36307212

BGI Signs Global Scientific Collaboration Agreement with Fred Hutchinson Cancer Research Center
Publish Date: 2018-11-06

SEATTLE, WA, November 6, 2018 – BGI, a global genomics company, and Fred Hutchinson Cancer Research Center (Fred Hutch), a world-renowned nonprofit research institute, have signed a Memorandum of Understanding (MOU) to discuss and explore collaborative projects in the field of genomics, with the goal of advancing research and educational opportunities and improving the health of people around the world.

Cancer is increasingly recognized as a health threat to individuals in both resource-rich countries and low- and middle-income countries. Through advances in next-generation sequencing (NGS), analyzing DNA can improve early cancer detection and diagnosis and optimize treatment plans.

The new MOU, signed by Dr. Jian Wang, chairman and co-founder of BGI and Dr. Gary Gilliland, president and director of Fred Hutch, provides a framework to support mutually agreeable projects in a range of research areas, including cancer genomics, immunology and infectious disease studies. These potential collaborative projects will benefit from BGI’s proprietary sequencing technology and global network and the deep expertise of Fred Hutch in cancer research and analysis.

Dr. Gary Gilliland, President and Director of Fred Hutch (Left) and Dr. Jian Wang, Chairmanand Co-founder of BGI Signs MOU

BGI and Fred Hutch also plan to discuss and explore building capacity and establishing partnerships with hospitals and research institutions in China and Africa. Preliminarily, the two organizations have discussed collaborating with hospitals in the Shenzhen area, where BGI is headquartered, and supporting the work of Fred Hutch in its collaboration with Uganda Cancer Institute,a comprehensive cancer facility that serves a five-country region with a total population of more than 100 million.

BGI provides a wide range of next generation sequencing services and a broad portfolio of genetic tests for medical institutions, research intuitions, and other public and private partners, with a mission to advance life science research and expand access to genomics for the benefit of humanity.

“We look forward to exploring and working with BGI on many important research projects, with the shared goal of ensuring that more people around the world can benefit from new discoveries and better treatments,” said Dr. Edus Houston Warren, head of Global Oncology at Fred Hutch.

“We are very fortunate to have an outstanding institution like Fred Hutch as a partner of BGI,” said Dr. Jian Wang, who first got to know Fred Hutch during his time as a research fellow at the University of Washington in the 1990s. “With the signing of this MOU, we are looking forward to working together closely to accelerate breakthroughs and improve people’s health and well-being, not only in the US and China but around the world.”

About Fred Hutchinson Cancer Research Center:

The Center was established in 1975 by Seattle surgeon Dr. William Hutchinson. Teams of world-renowned scientists and humanitarians at Fred Hutch work together to prevent, diagnose and treat cancer, HIV/AIDS, and other diseases.

About BGI:

BGI was founded in 1999 with the vision of using genomics to benefit mankind and has since become one of the largest genomics organizations in the world. With a focus on research and applications in the healthcare, pharmaceutical, conservation and environmental fields, BGI has a proven track record of innovative, high profile research that has generated over 1,600 publications. BGI’s goal is to make state-of-the-art genomics highly accessible to the global research community and clinical markets by integrating the industry’s broadest array of leading technologies, including BGI's own sequencing platform, economies of scale, and expert bioinformatics resources. BGI also offers a wide portfolio of transformative genetic testing products across major diseases, enabling medical providers and patients worldwide to realize the promise of genomics-based diagnostics and personalized healthcare.

Media Contact

Kristi Heim, BGI Deputy Director of Communications